Q2 saw 16% net sales growth, record wound management results, and a renewed BD partnership. Adjusted EBITDA rose to SEK 5.6 million, with strong cash flow and double-digit growth expected to continue, especially in wound management.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.